(NASDAQ: JSPR) Jasper Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.5%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.87%.
Jasper Therapeutics's earnings in 2026 is -$91,021,000.On average, 10 Wall Street analysts forecast JSPR's earnings for 2026 to be -$66,389,334, with the lowest JSPR earnings forecast at -$90,528,366, and the highest JSPR earnings forecast at -$35,259,889. On average, 6 Wall Street analysts forecast JSPR's earnings for 2027 to be -$51,473,841, with the lowest JSPR earnings forecast at -$83,918,536, and the highest JSPR earnings forecast at -$30,558,571.
In 2028, JSPR is forecast to generate -$48,143,741 in earnings, with the lowest earnings forecast at -$85,563,998 and the highest earnings forecast at -$27,914,079.